5 Key Takeaways

• 1

  Oral HRS-7535 significantly reduced hemoglobin A1c levels in patients with type 2 diabetes inadequately controlled by metformin.

• 2

  The trial involved 194 patients and demonstrated that HRS-7535 doses of 60 mg and 90 mg provided similar glycemic control.

• 3

  Patients receiving HRS-7535 achieved greater reductions in fasting plasma glucose and postprandial glucose compared to placebo.

• 4

  Gastrointestinal adverse events were common but mostly mild or moderate, with higher rates in the 60-mg dose group.

• 5

  The study's findings may not directly apply to Western populations due to differences in body mass index and diabetes characteristics.